- Rapid communication
- Open Access
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
Journal of Hematology & Oncology volume 10, Article number: 84 (2017)
Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success. The mechanism of action of trabectedin depends on the status of both the nucleotide excision repair (NER) and homologous recombination (HR) DNA repair pathways. Trabectedin results in DNA double-strand breaks. We hypothesized that PARP-1 inhibition is able to perpetuate trabectedin-induced DNA damage.
We explored the effects of combining a PARP inhibitor (rucaparib) and trabectedin in a large panel of soft-tissue sarcoma (STS) cell lines and in a mouse model of dedifferentiated liposarcoma.
The combination of rucaparib and trabectedin in vitro was synergistic, inhibited cell proliferation, induced apoptosis, and accumulated in the G2/M phase of the cell cycle with higher efficacy than either single agent alone. The combination also resulted in enhanced γH2AX intranuclear accumulation as a result of DNA damage induction. In vivo, the combination of trabectedin and rucaparib significantly enhanced progression-free survival with an increased percentage of tumor necrosis.
The combination of PARP inhibitor and trabectedin is beneficial in pre-clinical models of soft-tissue sarcoma and deserves further exploration in the clinical setting.
Up to 40% of patients diagnosed with localized soft-tissue sarcoma (STS) will develop metastatic disease . Once metastases are detected, median survival is approximately 12 months, and treatment is mainly based on palliative chemotherapy . Single-agent doxorubicin is the first line standard treatment in this context. Trabectedin (Et-743) has been approved recently in the USA and in Europe for the management of patients with advanced liposarcoma or leiomyosarcoma who have failed to benefit from anthracycline-containing regimen. The 6-month progression-free rate is approximately 35–40% [3–7]. Therefore, the identification of potential agents to combine with this drug to improve patient outcome is crucial.
Even though the exact mechanism of action of trabectedin has not been fully elucidated, previous in vitro studies have demonstrated that trabectedin depends on the status of both nucleotide excision repair (NER) and homologous recombination (HR) DNA repair pathways [8–12]. NER is involved in the repair of DNA lesions induced by ultra-violet light, carcinogens, or platinum-based regimens used in chemotherapy . HR is predominantly involved in the repair of DNA double-strand breaks during the S or G2 phase of the cell cycle using the second undamaged chromosome as a template . Several pre-clinical studies reported that NER-deficient cells were more resistant to trabectedin than their NER-proficient counterparts [8, 9, 11, 12, 15]. Indeed, trabectedin adducts have been suggested to induce a trapping of NER factors, which result in increased levels of cytotoxic DNA damage [12, 13]. ERCC5 (XPG) endonuclease was suggested to be the main NER protein involved in this process [10, 16]. It was also shown that cells deficient in HR are more sensitive to trabectedin than their normal counterparts due to the persistence of DNA lesions and increased formation of replication-dependent double-strand breaks (DSBs) . Interestingly, BRCA1, a key regulator involved in DNA end resection during HR , is a marker that is part of a gene signature associated with sensitivity to trabectedin treatment . We have also reported that the status of the ERCC1, ERCC5, and BRCA1 genes can predict efficacy of trabectedin in STS patients [19, 20].
PARP-1 recognizes and binds to sites of single-strand DNA breaks (SSBs). In cancer therapeutics, accumulation of SSBs with PARP inhibition leads to the development of DSBs, which require competent HR repair to allow cell survival. PARP has also been shown to be involved in DSB repair pathways. PARP inhibitors (PARPinhs) have been shown to increase the persistence of DNA breaks and cytotoxicity of DNA-damaging agents [21, 22]. Rucaparib is one of the first PARPinhs that have been evaluated in the context of a clinical trial, including clinical trials involving cancer patients .
Given that both trabectedin and PARPinh mechanisms of action involve DNA repair machinery, we decided to explore the effects of the combination in soft-tissue sarcomas.
Cells and cell culture
All of the STS cell lines used in this study were derived from human surgical specimens of STS in the laboratory of Pr. Jean-Michel Coindre and Dr Frédéric Chibon (Institut Bergonié, Bordeaux, France) and after obtaining written informed patient consent (Table 1) and Institut Bergonié IRB approval. Each cell line was characterized by array comparative genomic hybridization for every ten replicates to verify that its genomic profile was still representative of the originating tumor sample. Cells were grown in RPMI medium 1640 (Sigma Life Technologies, Saint Louis, MO) in the presence of 10% fetal calf serum (Dutscher, France) in flasks. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO2.
Rucaparib and trabectedin were supplied by Euromedex (Souffelweyersheim, France) and Pharmamar (Madrid, Spain), respectively.
Antiproliferative and cytotoxic effects of trabectedin and rucaparib were first determined on nine cell lines using Cytation 3 technology (Colmar, France). Briefly, cells were seeded in 384-well plates and were then exposed to trabectedin and/or rucaparib for 72 h. Cells were then marked with propidium iodide (PI) and Syto 24 fluorochromes for 30 min. Quantitative fluorescence and cell imaging were performed with Cytation 3 at λ = 617 nm for PI and 521 for Syto 24.
Trabectedin and rucaparib effects on cell viability were also investigated using the MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (Sigma-Aldrich Chimie, Saint-Quentin-Fallavier, France) as an indicator of metabolically active cells. A known number (2000 or 3000) of STS cells was transferred into 96-well plates and incubated for 24 h before the addition of the test compound. The cells were then exposed for 72 h at 37 °C to an increasing concentration range of trabectedin and rucaparib. MTT at a final concentration of 0.5 mg/ml was added, and following incubation for 3 h, formazan crystals were dissolved in DMSO. Absorbance of the colored solution was measured on a microplate-photometer (Bio-Tek Instruments, Colmar, France) using a test wavelength of 570 nm and a reference wavelength of 630 nm. The concentration of substance required for 50% growth inhibition (IC50) was estimated with GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA).
Cell cycle analysis
Cell cycle distribution of the four cell lines was studied by examining DNA content using fluorescence-activated cell sorting and analyzed using Cell Quest Pro software (BD Biosciences, San Jose, CA, USA). 2 × 105 cells were seeded in 6-well plates, and after 24 h, the cells were treated for 48 h with two different concentrations of trabectedin and/or rucaparib, centrifuged at 1500 g for 5 min, and washed twice with PBS. The cells were then fixed with 70% ethanol at 4 °C overnight. Following ethanol removal, the cells were washed twice with PBS. Next, 300 μl of a PI and ribonuclease-containing solution were added to the cells and then analyzed by FACS. The data were analyzed with FlowJo v.7.6.3 software, and the results were expressed in terms of percentage of cells in a given phase of cycle.
For apoptosis assessment, 1.5 × 105 cells were seeded in 6-well plates. After 24 h, cells were treated with two doses of trabectedin and/or rucaparib for 72 h and exposed to FITC-Annexin V and PI according to the manufacturer’s protocol (BD Biosciences, Erembodegem, Belgium). This allows us to distinguish Annexin V-positive cells in early apoptosis from Annexin V- and PI-positive cells in late apoptosis. Cells were analyzed by flow cytometry using FL1 for Annexin V and FL2 for PI. Flow cytometry (FACScan; BD Biosciences) data were analyzed with FlowJo v.7.6.3 software.
PARP activity was measured in cell extracts using the HT PARP/apoptosis assay (Amsbio, Abingdon, UK) according to the manufacturer’s protocol. Briefly, 5 × 103 cells were seeded in a 96-well plate and exposed to one concentration of trabectedin and/or rucaparib for 48 h. After exposure, protein extracts were prepared, transferred to histone-coated plates, and tested for ribosylation reaction. PARP activity was evaluated by an ELISA method that semi-quantitatively detects poly(ADP-ribose) or PAR. Absorbance was correlated with PARP activity and was measured at 450 nm, and the percentage of inhibition relative to the untreated control was calculated as follows: C = net absorbance in the absence of induced apoptosis; D = net absorbance determined during apoptosis; % inhibition of PARP = (C−D)/C*100.
Cells were seeded on coverslips and treated with one concentration of trabectedin, rucaparib, or a combination of the two drugs for 72 h. The slides were then washed twice with PBS, fixed in 4% formaldehyde, and incubated with anti-phosphoγH2ax monoclonal antibody (Cell Signaling, Leiden, Netherlands) overnight and then with goat anti-rabbit Alexa Fluor 488 antibody (Invitrogen, Paisley, UK). The slides were then counterstained using 4,6-diamidino-2-phenylindole (Hoechst).
ERCC5, ERCC1, and BRCA1 mRNA expression and genotyping
Total RNA was extracted using an RNeasy kit according to the manufacturer’s instructions. Quantification of gene expression was performed using the ABI Prism 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). The following primers and 50 labeled fluorescent reporter dye (6-FAM) probes were used: For β-actin, the forward primer was 5′-TGA GCG CGC CTA CAG CTT-3′, the reverse primer was 5′-TCC TTA ATG TCA CGC ACG ATT T-3′, and the 5′-FAM ACC ACC ACG GCC GAG CGG 3′-tetramethylrhodamine (TAMRA) probe was used. For BRCA1, the forward primer was 5′-GGC TAT CCT CTC AGA GTG ACA TTT TA-3′, the reverse primer was 5′-GCT TTA TCAGGT TAT GTT GCA TGG T-3′, and the minor groove binder (MGB) 5′-FAM CCA CTC AGC AGA GGG-3′ nonfluorescent quencher (NFQ) probe was used. For ERCC1, the forward primer was 5′-GGG AAT TTG GCG ACG TAA TTC-3′, the reverse primer was 5′-GCG GAG GCT GAG GAA CAG-3′, and the 5′-FAM CAC AGG TGC TCT GGC CCA GCA CAT A 3′-TAMRA probe was used. For ERCC5, the forward primer was 5'-GAA GCG CTG GAA GGG AAG AT-3′, the reverse primer was 5′-GAC TCC TTT AAG TGC TTG GTT TAA CC-3′, and the MGB probe 5′-FAM CTG GCT GTT GAT ATT AGC ATT 3′-NFQ was used. Relative gene expression was calculated according to the comparative ΔΔCt method using β-actin as an endogenous control and commercial RNA controls (Stratagene, La Jolla, CA; Applied Biosystems) as calibrators.
Genomic index calculation
The genomic index (GI) was calculated for each profile of cell lines as follows: GI = A 2/C, where A is the total number of alterations and C is the number of involved chromosomes.
In vivo study
Cell lines xenografts
Four- to five-week-old female Ragγ2C-/- mice were used. Induction of tumor xenografts was performed by subcutaneous injection of 0.2 ml cell suspensions containing 5 × 106 live IB115 cells or by subcutaneous implantation of UPS tumor fragment (PDX) into the right flank of the mice. This study followed the Spanish and European Union guidelines for animal experimentation (RD 1201/05, RD 53/2013, and 86/609/CEE, respectively). Mice were randomized into control and treatment groups (n = 8 for vehicle and rucaparib groups and n = 12 for trabectedin and combination groups for IB115 and n = 5 for vehicle and rucaparib groups and n = 8 for trabectedin and combination groups in PDX) 2 weeks after the tumor became measurable (15 days after injection: day 1 of treatment). Mice were randomized in four groups: vehicle (NaCl0.9%), trabectedin alone (0.05mk/kg IV once a week), rucaparib alone (10 mg/kg IP five times per week), and both drugs (trabectedin once a week and rucaparib five times per week at 0.05 mg/kg and 10 mg/kg, respectively). Trabectedin and rucaparib were administered using 0.9% NaCl as the vehicle. The tumors were measured every 2–3 days with a caliper, and diameters were recorded. Tumor volumes were calculated using the formula: a 2 b/2, where a and b are the two largest diameters. The mice were sacrificed by cervical dislocation 1 week after treatment arrest, and the tumors were collected for histopathological analyses. Progression-free survival curves were established based on twofold tumor increase as event. All experimental manipulations with mice were performed under sterile conditions in a laminar flow hood. After the sacrifice of the mice, tumors were harvested in 10% paraformaldehyde. Tissue pictures was carried out with an Olympus CKX41 (×2.5) using image capture cellSens Entry software version 1.14 (Olympus, Rungis, France) for Windows, and percentage of necrosis was estimated by an anatomical pathologist.
Data were analyzed using the Student t test for comparison of two means and ANOVA followed by the Turkey’s multiple comparison tests for more than two groups; all the experiments were repeated in duplicate or triplicate. Data are represented as mean ± SD, and significant differences are indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.
The analysis of progression-free survival was using LogRank test (Mantel-Cox test).
Antiproliferative activity of trabectedin and rucaparib in STS cell lines
We studied the sensitivity of nine STS cell lines to trabectedin and rucaparib. The IC50 values for trabectedin (Et-743) and rucaparib are shown in Table 1. All of the cell lines were highly sensitive to trabectedin, with IC50 values ranging between 0.352 and 2.64 nM. Three out of nine cell lines were sensitive to rucaparib, with IC50 values ranging between 1.104 and 1.488 μM. The other cell lines were relatively resistant to rucaparib, with IC50 values ranging between 12 and 58.08 μM. We did not find any correlation between the expression status of DNA repair genes (ERCC1, ERCC5, BRCA1), genomic index, or mutational status of TP53 (wild-type or mutated) of the STS cells and sensitivity to rucaparib (Table 1).
Rucaparib blocks basal and trabectedin-induced PARP-1 enzymatic activity in leiomyosarcoma cells
PARylation significantly triggers the accumulation of several DNA damage response (DDR) proteins at DNA lesions and is, therefore, a marker of DNA damage. We evaluated the effects of trabectedin, rucaparib, and combination in PAR synthesis after 72 h of incubation to determine the extent of this effect. As expected, the rucaparib inhibited basal PARP-1 activity (reducing the amount of PARylated proteins) in all cell lines, and we observed an effect of trabectedin and combination of drugs only in leiomyosarcoma cells (IB136) (Fig. 1).
Trabectedin and rucaparib combination increases DNA damage
To quantify the extent of DNA damage, we also analyzed γ-H2AX expression after the different drug treatments using confocal microscopy. As shown in Fig. 2, the combination of trabectedin (Et-743) and rucaparib induced significantly higher levels of γ-H2AX expression only in two cell lines IB115 and IB111 cell lines. The expression of γ-H2AX was evident even with various concentrations of trabectedin as a single agent, which prevented the formation of DSBs.
Trabectedin and rucaparib are synergistic in STS cell lines
We studied the effects of the combination of rucaparib and trabectedin. Nine STS cell lines were exposed during 72 h to different combinations of both agents at a constant ratio of 1: trabectedin and rucaparib were mixed and diluted serially (usually twofold serial dilutions with several concentrations above and below the IC50 for the two drugs), and combination indices (CIs) were determined according to Chou et al. . The results are described in Table 2. Interestingly, we observed an additive or synergistic effect when using the MTT method in 80% of the STS cell lines (in particular in liposarcomas).
Trabectedin and rucaparib combination induces apoptosis and cell cycle arrest in STS cell lines
We studied the effects of trabectedin and rucaparib combination on apoptosis induction after 72 h of drug exposure as well as cell cycle effects after 48 h of treatment in the cell lines IB115, IB111, IB136, and 93T449. We observed that the drug combination (picomolar amounts of trabectedin and micromolar amounts of rucaparib) increased the rate of apoptosis in comparison with the drugs alone in IB111 and IB136 cell lines (Fig. 3). Furthermore, G2/M accumulation and a decrease in the G0/G1 peak were also observed after treatment with the drug combination (Fig. 4), particularly in the IB115 cell line.
Trabectedin and rucaparib combination reduces tumor growth in vivo
To further validate in vitro study, we performed in vivo studies to test the antitumor effects of the trabectedin and rucaparib combination. Xenografts were generated by subcutaneous injection of IB115 cells in ragγ2C-/- mice or by subcutaneous implantation of UPS tumor fragment (PDX). Animals were randomized in four groups and treated for 3 weeks. These groups included control (NaCl 0.9%), trabectedin (trabectedin alone; 0.05 mg/kg IV once a week), rucaparib (rucaparib alone; 10 mg/kg BID IP, five times per week), and combination. After 3 weeks of treatment, we observed a significant effect on progression-free survival (evaluated as the time span from the treatment start and the doubling of the initial tumor volume); median time to doubling was 17.1 days for combination, 14.8 days for trabectedin (p = 0.045), and 6.6 days for rucaparib (p < 0.0001) (Fig. 5b) in IB115 xenografts model. After 3 weeks of treatment, the mice were sacrificed and tumors were extracted, weighed, and evaluated by histopathology. No signs of toxicity were observed with the combination treatment. Evaluation of percentage of necrosis indicates a good relationship between necrosis and treatment efficacy; for the combination, there are 25% of tumors with at least 60% of necrosis while only 0 or 10% for vehicle and drugs alone. We observed the same results in UPS PDX model; the combination regimen reduced tumor volume in comparison with single agent (Fig. 5c) and evaluation of necrosis indicate, as well as in IB 115 xenografts model, a good correlation with treatment (Fig. 5c).
Trabectedin has been recently approved in the USA and Europe for the management of advanced STS in patients who have failed to benefit from anthracycline-containing regimens. However, the activity of this drug as a single agent is limited, with a median PFS of only 4 months. Thus, there is a need for a more active regimen for use in STS patients.
Several studies suggest that PARP inhibition may be relevant to treating soft-tissue sarcomas. For instance, it is well known that loss of BRCA-1 or BRCA-2 leads to sensitivity to PARP1 inhibition, resulting in apoptosis. Xing et al. reported that 29% of uterine leiomyosarcomas had decreased or completely absent BRCA-1 protein expression, which is postulated to be due to methylation of the BRCA-1 gene promoter . Schoffski et al. reported a decrease in BRCA-1 expression in 50% of soft-tissue sarcoma samples .
In addition, members of the Fanconi family of proteins are involved in double-strand DNA repair through activation of ATM and ATR and formation of a nuclear complex of five Fanconi family proteins. This complex subsequently co-localizes with BRCA1 and BRCA2 for DNA repair . Loss of function or expression of any of these proteins or “BRCA-ness” confers sensitivity to PARP1 inhibition [28, 29]. ATM loss has been reported in several sarcoma subtypes, such as leiomyosarcoma and rhabdomyosarcoma [30, 31]. Finally, loss of PTEN confers sensitivity to PARP1 inhibition . This molecular aberration is a crucial event in tumorigenesis of leiomyosarcoma  and occurs frequently in dedifferentiated liposarcomas , the most frequent sarcoma subtype.
Several pre-clinical studies have shown that combining PARP inhibitors with methylating agents (DTIC, temozolamide), alkylating agents (cyclophosphamide, ifosfamide), or doxorubicin may help treat soft-tissue sarcomas by increasing antitumor efficacy [35–38]. We have also reported that BRCA1 genotype status was predictive of trabectedin efficacy in patients with advanced STS [19, 20]. For all these reasons, we decided to investigate whether the combination of PARP inhibition with trabectedin confers additive or synergistic antitumor activity.
Our results show that the combination of trabectedin and rucaparib was synergistic, increasing apoptotic activity and arresting cell cycle at the G2/M phases in STS, in particular dedifferentiated liposarcomas, while we did not observed a synergistic effect in leiomyosarcomas. One possible explanation is that our LMS cell lines were P53 mutated, and it has been shown that trabectedin proapoptotic activity involve mainly P53 .Furthermore, we demonstrated that although both agents alone induced DNA damage through an accumulation of γH2AX foci in vitro, the combined use or trabectedin and rucaparib significantly increases this effect. We also observed this synergistic antitumor activity in vivo, where the drug combination increased significantly progression-free survival in comparison with trabectedin and rucaparib used as single agents.
In conclusion, to the best of our knowledge, we report here the first pre-clinical evidence that the combination of a PARPinh and trabectedin is synergistic in soft-tissue sarcomas. Interestingly, promising activity of this combination has also been observed in bone sarcomas . Our results are sufficient to design a clinical study with the aim of assessing the combination of PARPinh and trabectedin in the treatment of STS.
Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14:869–77.
Italiano A, Mathoulin-Pelissier S, Cesne AL, Terrier P, Bonvalot S, Collin F, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049–54. doi:10.1002/cncr.25538.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–93. doi:10.1200/JCO.2015.62.4734.
Kawai A, Araki N, Sugiura H, Ueda T, Yonemoto T, Takahashi M, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16:406–16. doi:10.1016/S1470-2045(15)70098-7.
Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–90. doi:10.1200/JCO.2004.02.098.
Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576–84. doi:10.1200/JCO.2005.01.180.
Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22:890–9. doi:10.1200/JCO.2004.05.210.
Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001;92:583–8. doi:10.1002/ijc.1221.
Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001;37:97–105. doi:10.1016/S0959-8049(00)00357-9.
Herrero AB, Martín-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66:8155–62. doi:10.1158/0008-5472.CAN-06-0179.
Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A. 2007;104:13062–7. doi:10.1073/pnas.0609877104. Epub:2007 July 26.
Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001;7:961–6. doi:10.1038/91008.
Hoeijmakers JHJ. DNA damage, aging, and cancer. N Engl J Med. 2009;361:1475–85. doi:10.1056/NEJMra0804615.
Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11:196–207. doi:10.1038/nrm2851.
D’Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, et al. Unique features of the mode of action of ET-743. Oncologist. 2002;7:210–6. doi:10.1634/theoncologist.7-3-210.
Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther. 2008;7:10–8. doi:10.1158/1535-7163.MCT-07-0192.
Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2009;11:138–48.
Martínez N, Sánchez-Beato M, Carnero A, Moneo V, Tercero JC, Fernández I, et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther. 2005;4:814–23. doi:10.1158/1535-7163.MCT-04-0316.
Laroche-Clary A, Chaire V, Le Morvan V, Neuville A, Bertucci F, Salas S, et al. BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. Br J Cancer. 2015;112:688–92. doi:10.1038/bjc.2014.624.
Italiano A, Laurand A, Laroche A, Casali P, Sanfilippo R, Le Cesne A, et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer. 2011;117:3445–56. doi:10.1002/cncr.25925.
Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011;105:1114–22. doi:10.1038/bjc.2011.382.
Avilla-Arroyo S, Nunez GS, Garcia-fernandez LF, Galmaricini CM. Synergistic effect of trabectedin and olaparib combination regimen in breast cancer cell lines. J Breast Cancer. 2015;18(4):329–38. doi:10.4048/jbc.2015.18.4.329.
Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14:7917–23. doi:10.1158/1078-0432.CCR-08-1223.
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi:10.1016/0065-2571(84)90007-4.
Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, et al. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res. 2009;69:8231–5. doi:10.1158/0008-5472.CAN-09-2543.
Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer. 2011;47:1006–12. doi:10.1016/j.ejca.2011.01.016.
Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9. doi:10.1038/nrc1457.
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109–15. doi:10.1158/0008-5472.CAN-06-0140.
Williamson CT, Muzik H, Turhan AG, Zamò A, O’Connor MJ, Bebb DG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther. 2010;9:347–57. doi:10.1158/1535-7163.MCT-09-0872.
Ul-Hassan A, Sisley K, Hughes D, Hammond DW, Robinson MH, Reed MW. Common genetic changes in leiomyosarcoma and gastrointestinal stromal tumour: implication for ataxia telangiectasia mutated involvement. Int J Exp Pathol. 2009;90:549–57. doi:10.1111/j.1365-2613.2009.00680.x.
Zhang P, Bhakta KS, Puri PL, Newbury RO, Feramisco JR, Wang JY. Association of ataxia telangiectasia mutated (ATM) gene mutation/deletion with rhabdomyosarcoma. Cancer Biol Ther. 2003;2:87–91. doi:10.4161/cbt.231.
Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1:315–22. doi:10.1002/emmm.200900041.
Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med. 2007;13:748–53. doi:10.1038/nm1560.
Puzio-Kuter AM, Laddha SV, Castillo-Martin M, Sun Y, Cordon-Cardo C, Chan CS, et al. Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma. Cell Death Differ. 2015;22:1785–91. doi:10.1038/cdd.2015.27.
Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 2005;52:25–33. doi:10.1016/j.phrs.2005.02.010.
Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. 2006;20:1709–11. doi:10.1096/fj.06-5916fje.
Bernges F, Zeller WJ. Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines—with special reference to cisplatin. J Cancer Res Clin Oncol. 1996;122:665–70. doi:10.1007/BF01209029.
Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728–37. doi:10.1158/1078-0432.CCR-06-3039.
Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, et al. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget. 2015;6:18875–90. doi: 10.18632/oncotarget.4303.
Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J. RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas. Cancer Invest. 2015;33(9):440–50. doi:10.3109/07357907.2015.1064534.
All authors were supported by Grant INCa-DGOS-Inserm 6046. The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
AI and AL designed the study and wrote the manuscrip; AL, VC, MK, MPA, and CR made the pre-clinical experiments; all co-authors were involved in data analysis, interpretation, and final manuscript validation. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
This study was approved by the IRB of Institut Bergonié, Bordeaux, France.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Laroche, A., Chaire, V., Le Loarer, F. et al. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. J Hematol Oncol 10, 84 (2017) doi:10.1186/s13045-017-0451-x